EUVIMEDEUVIMED entdecken
Crossref

Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status

Masashi Yamamoto iD, Akira Miyauchi iD, Yasuhiro Ito, Makoto Fujishima, Takahiro Sasaki iD, Takumi Kudo

Thyroid® · 2023

DOI: 10.1089/thy.2023.0046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thyroid®, 2023. Verfasst von Masashi Yamamoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Kuma Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: Thyroxine, Thyroid Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

During active surveillance (AS), serum thyrotropin (TSH) levels may affect papillary thyroid microcarcinoma (PTMC) progression. We investigated AS outcomes according to whether levothyroxine (LT4) treatment was administered. Patients and Methods: From 2005 to 2019, 2896 patients with low-risk PTMC underwent AS. Of these, 2509 patients were included: 2187 patients did not receive LT4 at diagnosis (group I), 1935 patients did not receive LT4 during AS (group IA), and 252 patients started LT4 during AS (group IB). The remaining 322 patients were administered LT4 before or at diagnosis (group II). The tumor volume doubling rate (TVDR) and tumor size based on ultrasound examination results and time-weighted detailed TSH scores were calculated. Disease progression was defined as tumor enlargement ≥3 mm and/or the appearance of novel lymph node metastasis.

Results

At diagnosis, group II had more high-risk features, such as younger age and larger tumors, than group I. However, group II had a lower disease progression rate (2.9% at 10 years) than group I (6.1%) ( p = 0.091). The disease progression rate of group IB (13.8% at 10 years) was significantly higher than that of groups IA (5.0%) and II (2.9%) ( p < 0.01). The TVDR of group IB before LT4 administration was significantly higher than that of groups IA and II (0.095 per year, −0.0085 per year, and −0.057 per year, respectively; p < 0.01), suggesting that patients with progression signs during AS were selectively prescribed LT4. The time-weighted detailed TSH score of group IB significantly decreased after LT4 administration compared with those before administration (3.35 and 3.05, respectively; p < 0.01). The TVDR also decreased from 0.13 per year to 0.036 per year ( p = 0.08). The proportions of patients with rapid or moderate growth decreased significantly after LT4 (from 26.8% to 12.5%, p < 0.01). A multivariable analysis revealed group IB status was independently associated with disease progression (odds ratio [OR] = 3.42 [CI 2.15–5.44], p < 0.01), whereas age ≥40 years and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThyroxineThyroid NeoplasmsAdultWatchful WaitingDisease ProgressionThyrotropinRisk FactorsHumansCarcinoma, PapillaryMiddle Aged

Stichwörter der Autor:innen

active surveillancedetailed thyrotropin scorelevothyroxinepapillary thyroid microcarcinomathyrotropintumor volume doubling rate

Substanzen

ThyroxineThyrotropin

Autor:innen und Institutionen

  • Department of Head and Neck Surgery, Kuma Hospital, Kobe, Japan.
  • Department of Surgery, Kuma Hospital, Kobe, Japan.
  • Department of Internal Medicine, Kuma Hospital, Kobe, Japan.

ORCID-Profile: Masashi Yamamoto, Akira Miyauchi, Takahiro Sasaki

Zitieren

APA

Yamamoto, M., Miyauchi, A., Ito, Y., Fujishima, M., Sasaki, T., & Kudo, T. (2023). Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status. Thyroid®. https://doi.org/10.1089/thy.2023.0046

Vancouver

Yamamoto M, Miyauchi A, Ito Y, Fujishima M, Sasaki T, Kudo T. Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status. Thyroid®. 2023. doi:10.1089/thy.2023.0046

BibTeX
@article{Yamamoto2023,
  author = {Yamamoto, Masashi and Miyauchi, Akira and Ito, Yasuhiro and Fujishima, Makoto and Sasaki, Takahiro and Kudo, Takumi},
  title = {Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status},
  journal = {Thyroid®},
  year = {2023},
  doi = {10.1089/thy.2023.0046}
}
Kostenlos starten →